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Abstract
Background: Hyperechogenicity of the substantia nigra (SN+), detected by transcranial sonography (TCS), was
reported as a characteristic finding in Parkinson’s disease (PD), with high diagnostic accuracy values, when
compared mainly to healthy controls or essential tremor (ET) group. However, some data is accumulating that the
SN + could be detected in other neurodegenerative and even in non-neurodegenerative disorders too. Our aim
was to estimate the diagnostic accuracy of TCS, mainly focusing on the specificity point, when applied to a range
of the parkinsonian disorders, and comparing to the degenerative cognitive syndromes.
Methods: A prospective study was carried out at the Hospital of Lithuanian University of Health Sciences from
January until September 2011. Initially, a TCS and clinical examination were performed on 258 patients and 76
controls. The General Electric Voluson 730 Expert ultrasound system was used. There were 12.8% of cases excluded
with insufficient temporal bones, and 4.3% excluded with an unclear diagnosis. The studied sample consisted of
the groups: PD (n = 71, 33.2%), ET (n = 58, 27.1%), PD and ET (n = 10, 4.7%), atypical parkinsonian syndromes (APS)
(n = 3, 1.4%), hereditary neurodegenerative parkinsonism (HDP) (n = 3, 1.4%), secondary parkinsonism (SP) (n = 23,
10.8%), mild cognitive impairment (MCI) (n = 33, 15.4%), dementia (n = 13, 6.1%), and control (n = 71).
Results: There were 80.3% of PD patients at stages 1 & 2 according to Hoehn and Yahr. At the cut-off value of 0.20 cm
2
of the SN+, the sensitivity for PD was 94.3% and the specificity - 63.3% (ROC analysis, AUC 0.891), in comparison to the
rest of the cohort. At the cut-off value of 0.26 cm
2, the sensitivity was 90% and the specificity 82.4%.
The estimations for the lowest specificity for PD, in comparison to the latter subgroups (at the cut-off values of
0.20 cm
2 and 0.26 cm
2, respectively) were: 0% and 33.3% to APS, 33.3% and 66.7% to HDP, 34.8% and 69.6% to SP,
55.2% and 82.8% to ET, 75% and 91.7% to dementia.
Conclusions: The high sensitivity of the test could be employed as a valuable screening tool. But TCS is more
useful as a supplementary diagnostic method, due to the specificity values not being comprehensive.
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Background
The burden of progressive neurodegenerative diseases in
the elderly population is continuously growing, empha-
sizing the need of improving diagnostics and treatment
[1]. Parkinson’s disease (PD) is the second most preva-
lent neurodegenerative disease after Alzheimer’sd i s e a s e
(AD) [1]. However, the diagnosis of PD or AD is based
solely on the clinical criteria, as there is no accurate bio-
logical or imaging marker to date for either of them
[1-3].
Single photon emission computed tomography
(SPECT) is the most widely used diagnostic tool in par-
kinsonian disorders. In PD, there is a diminished uptake
of the ligand, which usually correlates with the clinically
affected side, and with progression of PD [2]. But
SPECT does not differentiate between PD and other
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used, it raises the sensitivity, but not the specificity for
PD and syndromes [3,4]. Besides, SPECT is not widely
available and limited in terms of safety [2].
Both magnetic resonance imaging (MRI) and com-
puted tomography (CT) are used to evaluate the struc-
tural changes of the brain. These imaging methods are
not usually needed for the diagnosis, but find their place
and value if parkinsonism is purely unilateral or other-
wise atypical, which exclude secondary causes [3]. Both
MRI and CT have their own limitations related to avail-
ability, costs, contraindications and safety (CT) [2,3].
Among the new techniques, transcranial B-mode
duplex sonography (TCS) has been drawing a lot of
attention as an easily accessible and inexpensive imaging
method [5]. TCS is sharing some features of the func-
tional imaging methods, which is thought to detect very
early dysfunction of the nigrostriatal pathways [6]. This
probably demonstrates an increased vulnerability of the
extrapyramidal system, or even an increased risk of PD
development [6,7].
Hyperechogenicity of the SN (SN+), both in echo
intensity and size of area, has been repeatedly reported
as a characteristic TCS finding in PD patients. But it
can be also detected in some other neurodegenerative
and even in non-neurodegenerative disorders [8,9], or
related to aging [7,10,11]. Therefore, the issue regarding
sensitivity and specificity of TCS is still disputable (see
Figure 1 for the illustration of the observed SN+ in dis-
orders other than PD in our study). While many studies
have estimated specificity of TCS comparing PD patients
to healthy controls or essential tremor (ET) group
[5,12-22], to date, very few case control studies involved
patients with atypical parkinsonian syndromes (APS),
neurodegenerative hereditary (HDP) or secondary par-
kinsonism (SP) [4,23-27].
The aim of the present study was to estimate the diag-
nostic accuracy of TCS, mainly focusing on the specifi-
city point. TCS findings in PD patients were compared
to the controls and to the findings in patients with vari-
ety of parkinsonian syndromes, ET, mild cognitive
impairment (MCI) and dementia groups.
Figure 1 Hyperechogenicity of the SN detectable in various diseases, other than PD (.tif). TCS with the SN+ (hyperintensive signal marked
with white arrows) in a patient with essential tremor, A- in a patient with Stiff person syndrome, C- in a healthy control, D- in a case of
progressive supranuclear palsy, E- in a severely depressed subject, and F- in secondary (vascular) parkinsonism. All the pictures are made in our
laboratory with GE Voluson 730 Expert ultrasound system, with the permissions gained from all the patients to reproduce the images
confidentially.
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Enrolment of the patients and controls
The patients for TCS investigation were referred from
both Out-patient (n = 156, 72.9%) and In-patient (n =
58, 27.1%) units of Neurological Department of the Hos-
pital of Lithuanian University of Health Sciences (Kau-
nas, Lithuania). The study was conducted from January
2011 till September 2011. Initially, a total of 258 adult
patients with extrapyramidal symptoms and signs were
invited to take part in the study. From a total sample,
we had to exclude 33 (12.8%) of the subjects because of
bilateral temporal acoustic bone insufficiency. For 11
(4.2%) of the patients, the diagnosis was still not clear
after a six month follow-up period. Therefore 214
patients were enrolled for further analysis.
The control group consisted of 71 matched-to-PD
group individuals, who were without signs of movement
or cognitive disorders. They were referred for extracra-
nial artery duplex ultrasound scanning.
A clinical diagnosis after a six month follow-up was
chosen as a gold diagnostic standard for PD [3]. When
the diagnosis remained unclear clinically, or TCS results
were doubtful and not consistent with the clinical find-
ings, SPECT with presynaptic
123I labelled Ioflupane
ligand was employed. For the patients with pyramidal
signs or other atypical symptoms, brain CT or MRI scans
were performed by experienced neuroradiologist (RG).
The 214 patients group consisted of 71 (33.2%) PD
patients (meeting the criteria of the United Kingdom
Parkinson’s Disease Society Brain Bank [28], 58 (27.1%)
ET patients, 10 (4.7%) patients with signs and symptoms
of both PD and ET (a combined form), and 23 (10.8%)
patients to whom secondary parkinsonism (SP) was
diagnosed. In addition, there were 3 (1.4%) patients with
atypical parkinsonian syndrome (APS), 3 (1.4%) patients
with hereditary neurodegenerative parkinsonism (HDP),
33 (15.4%) patients with mild cognitive impairment
(MCI), and 13 (6.1%) with dementia.
The entire spectrum of parkinsonian syndromes,
which were tested, consisted of APS (2 patients with
progressive supranuclear palsy and 1 with multisystem
atrophy), HDP (1 patient with early-onset Huntington’s
disease (HD), 2 patients with Wilson’s disease (WD)),
SP (4 patients with hydrocephalus, 2 patients with extra-
pyramidal signs of vascular origin, 2 patients with
tumor, 2 post-traumatic patients, 1 post-infective
patient, 1 psychogenic, 1 patient with toxins-induced
parkinsonism, 1 patient with drugs induced parkinson-
ism, 1 patient with amyotrophic lateral sclerosis, and 8
patients of undefined etiology). We included the patients
both with clinically suspected (de novo) parkinsonian
spectrum disorders (n = 104, 61.9%), and with clinically
well defined diagnoses, the latter having already had
prescribed treatment (n = 64, 38.1%).
The dementia group consisted of 6 (46.2%) patients
with Alzheimer’s disease, 6 (46.2%) patients with vascu-
lar dementia, and 1 (7.6%) patient with a not yet deter-
mined dementia type.
Before the study was initiated, permission from the
Regional Ethical Committee of Kaunas (Lithuania) was
obtained. All participants gave written informed consent
according to the Declaration of Helsinki.
Clinical and instrumental approach
The study had a prospective manner. A TCS, clinical
examination (mainly extrapyramidal tone of the muscles,
tremor and/or bradykinesia, its location), a structural
interview (family history, head traumas, symptom dura-
tion, type of a job, intoxications, most prominent motor
and non-motor symptoms at the time of examination),
also subjective (Hospital Anxiety and Depression Scale
(HAD) [29] and objective scales (the Unified Parkinson’s
Disease Rating Scale (UPDRS) (DS) [30] were employed.
The Mini Mental State Examination (MMSE) [31] and
the Alzheimer’s Disease Assessment Scale- Cognitive
(ADAS Cog) [32] were used for the cognitive assessment.
Methods of TCS
A PA2-5, wide band, phased array sector transducer (f0
=1 . 4M H z ,b a n dw i t h1 . 3-4M H z ,f o o t p r i n t2 0×1 4
mm (128 elements)), on the commercially available
ultrasound system, Voluson 730 Expert (General Electric
Healthcare, Austria), was used for all examinations. At
first, a calibration of the ultrasound machine with a
phantom was performed, cooperating with the scientists
f r o mt h eU n i v e r s i t yo fT e c h n o l o g yo fK a u n a s( A S ,A L )
[33]. The parameters of the ultrasound system were
chosen as recommended by Walter U et al. [34]. The
transducer was placed over the pre-auricular temporal
acoustic window on both sides of the patients and con-
trols. By laying the patients and healthy subjects in a
supine position in a darkened room, and by focusing at
a depth of 16.8 cm/55 Hz, at a power of 100 W, we
achieved optimal image quality of the structures at the
midbrain level and at other planes. The overall gain and
degree of compression (TGC curve) were manually
adapted if necessary, with a lateral gain control of the
machine. A mechanical index of 0.7 and a thermal index
of 0.3 were ensured according to recommendations for
the safe use of diagnostic ultrasound equipment. TCS
on all of the participants was performed by one of the
authors (KL), who was blind to the initial diagnosis of
each patient and control. The sequences of TCS images
of all subjects were obtained in AVI format. Each
sequence consisted of approximately 200 frames (size of
single frame 600 × 800 pixels, single pixel size 0.0421
cm). After freezing the best image for the measurements
(the largest plot of the SN), it was zoomed three-fold.
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the ipsilateral SN to transducer was measured, along
with other structures on the contralateral side. Video
footage was acquired using 2D cine scanning mode, and
was stored for reviews after TCS examination.
Parameters of TCS analysis
The SN+ was recorded in echo intensity (using qualita-
tive 5° visual grading) and in size of area (planimetry,
outlined manually in cm
2). Grade I of the SN echogeni-
city was defined as the same echogenicity as the brain-
stem, grade II - when clearly detectable from the
brainstem, grade III- lower signal intensity when com-
paring to perimesencephalic cisterns, grade IV - the
same to perimesencephalic cisterns, grade V - higher
than perimesencephalic cisterns [35].
For the quantitative evaluation, we calculated the
mean value of the SN echogenicity, from the measure-
ments of the healthy controls, as 0.14 ± 0.06 cm
2 (mean
± 1 SD). We followed the recommendations of Berg D
et al., to use the mean + 1 or 2 SD as an upper norm
value [36]. We treated the SN+ if at least one side was
enlarged, and the enlargement was by > 0.20 cm
2.
Together with the SN, other TCS parameters were
recorded. That included the diameters of the third and
lateral ventricles, and the echogenicity of the raphe, red,
lentiform, caudate nuclei and of the central grey matter.
Statistical analysis
A database was created using Microsoft Office Excel
2003. For the statistical analysis, data was exported to
the statistical package IBM SPSS version 19 (IBM,
USA). For the two group comparison of unpaired, non-
parametric data, Mann-Whitney U test and Fisher’s
exact tests were used. For three or more groups, the
Kruskal-Wallis H test was used. For parametric data,
analysis of variance (ANOVA) was used, for the com-
parison between three or more groups. Where appropri-
ate, the corrections for multiple comparisons were
performed. Post hoc tests of Tukey and LSD were per-
formed where necessary, to obtain the exact differences
between the groups by multiple comparisons. For cate-
gorical data, c
2 criterion was used. The cut-off value
was established by Receiver Operating Characteristics
(ROC) analysis. Correlation analysis of non-parametrical
data was performed by Spearman’s rank correlation. The
P value of less than 0.05 was used as the criterion for
statistical significance.
Results
Sample characteristics
Due to permeable acoustic temporal bone windows
being on both sides, bilateral investigation was per-
formed on 141 (65.9%) of the 214 TCS examination
patients. Unilateral investigation was carried out on the
remaining 73 (34.1%) patients. The majority of the
excluded patients (n = 33, 12.8%) with insufficient tem-
poral acoustic bones were of a female gender (91.9%),
with only 8.1% being male. According to the age, they
were of 70.7 ± 7.8 years.
A summary of demographic and clinical characteristics
of the patients (n = 214) and controls (n = 71), is given
in additional file [see Additional file 1]. Statistical find-
ings from multiple comparisons revealed that PD
patients were significantly younger compared to the
dementia group (63.8 ± 10.1 years vs. 71.0 ± 11.8 years,
respectively), were of predominant male gender (57.8%),
and 90.1% with detectable raised extrapyramidal tone.
There was positive family history for 14.1% of PD
patients, compared to 34.5% from the ET group. A quite
s i g n i f i c a n tp a r t( 1 6 . 9 % )m e n t i o n e dc o n t a c tw i t ht o x i c
agents at work in the PD group.
The different clinical subtypes of PD were as follows:
20 (28.1%) patients were tremor-predominant, 19
(26.8%) were bradykinesia/akinesia predominant and 32
(45.1%) had a mixed type of the disease. According to a
relative level of disability (disease stage by Hoehn and
Yahr scale), the patients were classified as having stage
1-22 (31.0%), stage 2-35 (49.3%), stage 3-13 (18.3%), and
stage 4-1 (1.4%) in the PD group. The median symptom
duration was 3 years. The UPDRS part III scores for PD
patients were (mean ± SD) 12.63 ± 1.73 points (a range
from 4 to 23 points).
The lowest cognitive scores were counted for the SP
(MMSE 18.0 ± 2.8 points) and dementia (MMSE 20.6 ±
2.4 points) groups. The Adas Cog scores differed statis-
tically significantly between MCI and dementia groups
(17.9 ± 4.7 vs. 29.2 ± 8.1 points).
TCS findings
The results of TCS examination are presented in addi-
tional file [see Additional file 2]. The SN+ was detected in
66 (92.96%), and it was negative to 5 (7.04%) patients of
the PD group. The SN+ was present among the majority
of PD patients bilaterally (n = 51, 77.3%). We detected a
high percentage of the SN+ at a threshold of 0.20 cm
2 in
other parkinsonian spectrum disorders (70% in PD plus
ET, 66.7% in APS, 52.1% in SP, 33.3% in HDP groups). In
the ET group it was 31%. When compared to the control
group, a higher frequency of the SN+ was detected in the
dementia group (15.6% vs. 11.2%, respectively).
The SN greatest plot between the groups quantita-
tively was then compared. Tukey post hoc analysis
revealed, that it did not differ the plot of the PD group
from PD plus ET group (p = 0.995), APS (p = 0.378)
and HDP (p = 0.348). But it demarcated clearly from
the rest of the groups (ET, SP, MCI, dementia and
controls).
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were successively distributed as grade I- 0 (0%), grade
II- 5 (7.4%), grade III- 32 (47.1%), grade IV- 30 (44.1%),
grade V- 1 (1.5%). A positive correlation was found
between the intensity of the SN signal (grade), and the
plot (cm
2) in all the patient groups (Spearman’sr h o=
0.676, p < 0.001).
In the PD group, the mean plot of the SN+ differed in
each of the clinical subtypes of the disease. This was the
largest in the hypokinetic/akinetic 0.47 ± 0.16 cm
2
(ANOVA, F = 4.13, p = 0.01) variant. A statistically sig-
nificant correlation was detected between the hypere-
chogenic plot of the SN on the right side (p = 0.02), but
not on the left side (p = 0.06), with contralateral clinical
symptoms at onset of PD.
A diameter of the third ventricle differed statistically sig-
nificantly between the PD and SP groups (p =0 . 0 4 ) ,a n d
also between the PD and dementia groups (p = 0.02). The
diameter of the right lateral ventricle also differed signifi-
cantly between the PD and MCI (p =0 . 0 4 ) ,a n dw h e n
compared to the dementia group (p = 0.03). Taking into
account the results from all the groups, we found that the
diameter of the third and of the lateral ventricles corre-
lated positively with age (Spearman’s rho = 0.494, p <
0.001, and Spearman’s rho = 0.233, p = 0.002, respectively).
Specificity and sensitivity of TCS
The cut-off value for the plot of the SN was established
using ROC curve with the sensitivity of 94.3% for PD,
which corresponded to an area of 0.20 cm
2 (AUC
0.891), and at this cut-off value the specificity was
63.3%. When the cut-off value reached 0.26 cm
2,t h e
sensitivity was 90% and the specificity 82.4%, when com-
paring the PD group to the rest of our cohort.
When separately comparing the PD group to the ET
group, ROC analysis revealed that at the cut-off value of
0.20 cm
2, the diagnostic specificity was 55.2%, and at
the cut-off value of 0.26 cm
2 it was 82.8% (AUC 0.903)
(see Table 1 - Diagnostic accuracy of TCS for PD).
Then the PD group was compared to other parkinson
spectrum disorders individually. The lowest diagnostic
specificity for PD of 0% to 33.3% was estimated at both
the cut-off values of 0.20 cm
2 and 0.26 cm
2 (AUC
0.903) respectively, when compared to APS. However,
the third ventricle diameter above 10 mm raised the
diagnostic specificity (vs. APS) up to 66.6%. The same
was reached when comparing the PD group to the SP
group. The diameter of the third ventricle greater than
10 mm raised the specificity up to 78.3%.
When compared the PD group to the cognitive syn-
dromes, the specificity was estimated much lower (75%),
when compared to the dementia group at the cut-off
value of 0.20 cm
2 (AUC 0.905).
Discussion
Our study addressed the important issue of the sensitiv-
ity and specificity of TCS to determine clinical diagnosis
of PD. It is a matter of concern about false positives
(the subjects with the SN+ detected by TCS, but with-
out PD) in screening tests, as we don’tw a n tt ot e l l
s o m e o n et h a tt h e yh a v eas e r i o u sd i s e a s ew h e nt h e yd o
not really have it. The specificity of the TCS refers to
the ability of the test to correctly identify those patients
without PD. In this pilot study, by ROC analysis, we cal-
culated the sensitivity of TCS for PD 94.3%, and the
specificity 63.3% at the cut-off value of 0.20 cm
2,w h e n
compared to the rest of the cohort. While at the cut-off
v a l u eo f0 . 2 6c m
2, the sensitivity was calculated 90%,
and the specificity 82.4%.
The cut-off values, developed in our laboratory for the
SN+ threshold of 0.20 cm
2 [4,12-14,17,20,21,24,25] and
of 0.26 cm
2 [37], were consistent with the findings of
other authors. The new feature of our study was the dif-
ferent ultrasound system, which was not employed and
reported by previous studies, confirming that data
acquired by this device is comparable to other ultra-
sound systems.
The specificity was markedly lower, when in compari-
son to the results, published by some other authors
[14,25-27]. This finding raised issues on the diagnostic
specificity of TCS in the differentiation of Parkinson
spectrum disorders. SPECT has the same limitations,
Table 1 Diagnostic accuracy of TCS for PD
Accuracy Cut-off
value
(cm
2)
Parkinson spectrum
disorders
Cognitive
disorders
Control
n=7 1
PD
n=7 1
ET
n=5 8
APS
n=3
HDP
n=3
SP
n=2 3
MCI
n=3 3
D
n=1 3
Se (%) 0.20 94.3 N/A N/A N/A N/A N/A N/A N/A
0.26 90 N/A N/A N/A N/A N/A N/A N/A
Sp (%) 0.20 N/A 55.2 0 33.3 34.8 89.7 75 83.3
0.26 N/A 82.8 33.3 66.7 69.6 93.1 91.7 95.8
Abbreviations: N/A not applicable, TCS transcranial sonography, Se sensitivity, Sp specificity, PD Parkinson’s disease, ET essential tremor, APS atypical parkinsonian
syndromes, HDP hereditary degenerative parkinsonism, SP secondary parkinsonism, MCI mild cognitive impairment, D dementia
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was especially evident when comparing the PD to APS
(33.3%), to HDP (66.7%) and to SP (69.6%) groups, even
at the cut-off value of 0.26 cm
2. Although in a less pre-
valent manner, the SN+ could be detected in some
other neurodegenerative diseases, as well as in some
subgroups of the patients with non-degenerative diseases
and in disorders associated with an increased risk of PD
[38]. If it is known that the SN+ in these disorders is
also present already at the preclinical stages, this might
contribute to a lower diagnostic specificity [9].
It is important to emphasize that the values of diag-
nostic accuracy were counted solely on the SN measure-
ments, and the integration of the other TCS features
(the diameters of the ventricles, echogenicity of other
basal ganglia) proved helpful. We noticed the common
signs detected by TCS in PD patients were: 1) more fre-
quent bilateral involvement of the SN (77.3%), 2) evi-
dently a much larger area of the SN+ (mean 0.42 cm
2 in
the PD group, while in APS, HDP, SP approximately
0.25 cm
2), 3) with a mean third ventricle diameter of
0.58 cm (similar to the ET and MCI groups), 4) an
absent or interrupted nuclei raphe in the majority of
cases, and 5) the moderately increased central grey mat-
ter. We introduced the latter parameter (a potentially
useful ultrasound marker), as this area is usually evalu-
ated during MRI studies in parkinsonian syndromes and
resembles possible periaqueductal gliosis. The central
grey matter was the most evidently hyperechogenic in
dementia, APS and HDP groups.
A comparison to the degenerative cognitive syndromes
also added some new information. The lower diagnostic
specificity for PD when compared to the dementia
group (75% at the cut-off value 0.20 cm
2 of the SN)
should be evaluated critically, as one patient of the
group exhibited clearly detectable extrapyramidal tone
of the muscles, two of the patients- subtle slow move-
ments, proving possible involvement of extrapyramidal
nervous system in the pathologically aging brain. The
main TCS parameters, which enabled to raise diagnostic
specificity, were the significantly wider diameters of the
third and lateral ventricles in the dementia group.
It is necessary to emphasize that in our study the
majority of PD patients were at the early stage of the
disease (80.3%), and of the de novo diagnosis (61.9%).
However, some of the patients fell into different cate-
g o r i e sw h e r ei tw a sn o tp o s s i b l et oc l e a r l yd i s t i n g u i s h
PD and ET after 6 months of the follow-up period.
Those patients, along with the patients, who had totally
unclear diagnosis, were excluded from any further analy-
sis. This could have a positive influence on the values of
the diagnostic accuracy. Another limitation of the study
was finding a small number of cases in APS and HDP
groups. We have chosen the control group from the
subjects, who were referred to the vessel ultrasound,
who were suspected to have vascular disorders. The
main limitation of the TCS method itself was that there
was a high number of bilateral temporal acoustic bone
insufficiency found (12.8%), mainly among older female
patients.
We have found the highest plots of the SN+ in the
hypokinetic/akinetic PD type. This feature is in parallel
with the results, where the SN+ correlated with the
bilateral bradykinesia and rigidity [35]. The SN+ on the
right side was larger to the contralateral clinical symp-
toms on disease presentation (p =0 . 0 2 1 ) ,b u tw a sn o t
replicated on the left side to the contralateral clinical
symptoms (p = 0.055). This was consistent with some
other studies, where signal extension was usually larger
contralaterally to the more clinically affected side
[36,37].
Conclusions
The lowest specificity of the TCS for PD was detected
by making comparisons to the other parkinsonian syn-
dromes, ET and dementia. The sensitivity was high
(94.3% and 90% at the cut-off values of 0.20 cm
2 and
0.26 cm
2, respectively), based solely on the measures of
the SN area, and taking into account the early stages of
PD and the heterogeneous sample. The high sensitivity
of the test could be employed as a valuable screening
tool for PD, but is better to be used as a supplementary
diagnostic method, due to the specificity values not
being comprehensive. However, the diagnostic specificity
could be raised by combining other TCS parameters, the
results of clinimetric scales, clinical information and
other imaging tests.
Additional material
Additional file 1: Demographic and clinical characteristics of the
patients and controls (Table 2.doc). There are given characteristics of
all the studied subgroups of the patients, and control subjects in detail.
After the six months of follow-up, we grouped the sample of patients
into parkinson spectrum disorders and patients with cognitive deficits.
The statistical differences were counted.
Additional file 2: Results of TCS (Table 3.doc). Presented in this table
are all the results, gained after performing TCS with the statistically
counted differences. The measurements were presented according to
the groups of PD patients and controls.
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